


Antitumor agent-71

Cat. No.:	HY-146250
CAS No.:	2011756-99-1
Molecular Formula:	C ₂₆ H ₃₁ N ₅ O ₄ S
Molecular Weight:	509.62
Target:	Microtubule/Tubulin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antitumor Agent-71 is an antiproliferative activity antitumor agent and against tumor cell lines with IC ₅₀ values ranging from 3.98-15.70 μM. Antitumor Agent-71 is an antitumor agent that can inhibit tubulin polymerization.								
IC₅₀ & Target	3.98/15.70/10.48/5.38 μM								
In Vitro	<p>Antitumor agent-71 (0.002-20 μM; 48 hours) inhibits the cell line HepG2, MCF-7, MIA PaCa-2, and Bel-7402 growth in a dose-dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2, MCF-7, MIA PaCa-2, and Bel-7402^[1].</td> </tr> <tr> <td>Concentration:</td> <td>0.002-20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48h</td> </tr> <tr> <td>Result:</td> <td>Showed antitumor activity against HepG2, MIA PaCa-2, MCF-7, and Bel-7402 cell lines with the IC₅₀ values of 3.98/15.70/10.48/5.38 μM.</td> </tr> </table>	Cell Line:	HepG2, MCF-7, MIA PaCa-2, and Bel-7402 ^[1] .	Concentration:	0.002-20 μM	Incubation Time:	48h	Result:	Showed antitumor activity against HepG2, MIA PaCa-2, MCF-7, and Bel-7402 cell lines with the IC ₅₀ values of 3.98/15.70/10.48/5.38 μM.
Cell Line:	HepG2, MCF-7, MIA PaCa-2, and Bel-7402 ^[1] .								
Concentration:	0.002-20 μM								
Incubation Time:	48h								
Result:	Showed antitumor activity against HepG2, MIA PaCa-2, MCF-7, and Bel-7402 cell lines with the IC ₅₀ values of 3.98/15.70/10.48/5.38 μM.								
In Vivo	<p>Antitumor agent-71 (10-20 mg/kg; intravenous injection; twice a day; 20 days) shows inhibitory effects and inhibits HepG2 cell line in nude mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>HepG2 model BALB/c nude mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10mg/kg, 20mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; twice a day; 20 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth in a dose-dependent manner.</td> </tr> </table>	Animal Model:	HepG2 model BALB/c nude mice ^[1]	Dosage:	10mg/kg, 20mg/kg	Administration:	Intravenous injection; twice a day; 20 days	Result:	Inhibited tumor growth in a dose-dependent manner.
Animal Model:	HepG2 model BALB/c nude mice ^[1]								
Dosage:	10mg/kg, 20mg/kg								
Administration:	Intravenous injection; twice a day; 20 days								
Result:	Inhibited tumor growth in a dose-dependent manner.								

REFERENCES

[1]. Lianqi Sun, et al. Design, synthesis, and evaluations of the antiproliferative activity and aqueous solubility of novel carbazole sulfonamide derivatives as antitumor agents. *Bioorg Chem.* 2020 Jun;99:103766.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA